Difference between revisions of "Hypereosinophilic syndrome - null regimens"
Jump to navigation
Jump to search
(Created page with "The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development o...") |
m |
||
| Line 29: | Line 29: | ||
</div> | </div> | ||
===References=== | ===References=== | ||
| − | # '''GSK 100185:''' Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530. [https://doi.org/10.1056/NEJMoa070812 link to original article] | + | # '''GSK 100185:''' Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530. [https://doi.org/10.1056/NEJMoa070812 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18344568/ PubMed] [https://clinicaltrials.gov/study/NCT00086658 NCT00086658] |
## '''Update:''' Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. Epub 2012 Oct 4. [https://doi.org/10.1016/j.jaci.2012.07.055 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3558744/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23040887/ PubMed] | ## '''Update:''' Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. Epub 2012 Oct 4. [https://doi.org/10.1016/j.jaci.2012.07.055 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3558744/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23040887/ PubMed] | ||
# '''NIAID 14-I-0081:''' Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019 Apr 4;380(14):1336-1346. [https://doi.org/10.1056/NEJMoa1812185 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557265/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30943337/ PubMed] [https://clinicaltrials.gov/study/NCT00001406 NCT00001406] | # '''NIAID 14-I-0081:''' Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019 Apr 4;380(14):1336-1346. [https://doi.org/10.1056/NEJMoa1812185 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557265/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30943337/ PubMed] [https://clinicaltrials.gov/study/NCT00001406 NCT00001406] | ||
Latest revision as of 14:26, 27 January 2024
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main HES page for regimens that include active disease-modifying treatment.
All lines of therapy
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Rothenberg et al. 2008 (GSK 100185) | 2004-2006 | Phase 3 (C) | Mepolizumab | Inferior primary endpoint |
| Kuang et al. 2019 (NIAID 14-I-0081) | 2014-2017 | Randomized Phase 2, fewer than 20 pts (C) | Benralizumab | Seems to have inferior primary endpoint |
No active disease-modifying treatment.
References
- GSK 100185: Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530. link to original article PubMed NCT00086658
- Update: Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. Epub 2012 Oct 4. link to original article link to PMC article PubMed
- NIAID 14-I-0081: Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019 Apr 4;380(14):1336-1346. link to original article link to PMC article PubMed NCT00001406